Skin hardening in treatment for osteoporosis

Previous research has shown that balicatib, a cathepsin K inhibitor used in osteoporosis, causes hardening of the skin

Researchers have now investigated this phenomenon further. Of 709 patients treated with balicatib, nine developed skin hardening and were diagnosed with morphea-like skin changes. Patients taking the lowest dose of balicatib or placebo did not did experience skin hardening. Discontinuation of balicatib resulted in complete resolution of symptoms in eight patients and partial resolution in one. These results suggest that skin hardening is a dose-related adverse effect associated with balicatib.

Runger TM, Adami S, Benhamou CL et al. J Am Acad Dermatol 2011 (article in press)

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Removed: Xepin.
Use our constantly updated shortages...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests